Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: Data from FOS (Fabry Outcome Survey)

Journal of Medical Genetics

Volumn 42, Issue 3, 2005, Pages 247-252

  Hoffmann, B ^a   Garcia De Lorenzo, A ^b   Mehta, A ^c   Beck, M ^d   Widmer, U ^e   Ricci, R ^f  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA;

ANALGESIA; ANALGESIC ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; HUMAN RELATION; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; MOOD; PAIN; PAIN ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SLEEP; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WALKING;

ALPHA-GALACTOSIDASE; DATABASES, FACTUAL; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; LONGITUDINAL STUDIES; MALE; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 15044357727     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.025791     Document Type: Review

References (49)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
2. Peters FP, Vermeulen A, Kho TL. anderson-Fabry's disease: alpha-galactosidase deficiency. Lancet 2001;357:138-40.
3. MacDermot KD, Holmes A, Miners AH. anderson-Fabry disease: clinical manifestations, and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60.
4. Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 2002;19:575-86.
5. Ries M, Mengel E, Kutschke G, Kim KS, Birklein F, Krummenauer F, Beck M. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 2003;26:413-14.
6. Schiffmann R, Floeter MK, Dambrosia JM. Enzyme replacement therapy improves peripheral nerve, and sweat function in Fabry disease. Muscle Nerve 2003;28:703-10.
7. Gallagher RM. Low back pain, health status, and quality of life in older adults: challenge, and opportunity. Pain Med 2003;4:305-7.
8. Phillips CJ. [Pain management: health economics, and quality of life considerations]. Drugs 2003;63:47-50.
9. Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. Pain Med 2004;5(suppl 1):S9-27.
10. Grunfeld JP, Lidove O, Joly D, Barbey F. Renal disease in Fabry patients. J Inherit Metab Dis 2001;24(suppl 2):71-4.
11. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin HA III, Kopp JB. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity, and genetic mutations on clinical course. Medicine (Baltimore) 2002;81:122-38.
12. Obrador GT, Ojo A, Thadhani R. End-stage renal disease in patients with Fabry disease. J Am Soc Nephrol 2002;13(suppl 2):S144-6.
13. Beer G, Reinecke P, Gabbert HE, Hort W, Kuhn H. Fabry disease in patients with hypertrophic cardiomyopathy (HCM). Z Kardiol 2002;91:992-1002.
14. Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in, anderson-Fabry disease. J Am Soc Nephrol 2002;13(suppl 2):S147-9.
15. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in, anderson Fabry disease. Z Kardiol 2002;91:786-95.
16. Linhart A, Magage S, Palecek T, Bultas J. Cardiac involvement in Fabry disease. Acta Paediatr Suppl 2002;91:15-20.
17. Brady RO, Schiffmann R. Clinical features of, and recent advances in therapy for Fabry disease. JAMA 2000;284:2771-5.
18. Schiffmann R. Natural history of Fabry disease in males: preliminary observations. J Inherit Metab Dis 2001;24(suppl 2):15-17.
19. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruni K, Gal A, Bunge S, Beck M. anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-24.
20. Whybra C, Wendrich K, Ries M, Gal A, Beck M. Clinical manifestation in female Fabry disease patients. Contrit Nepnrol 2001b;136:245-50.
21. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IUB study. J Inherit Metab Dis 2003;26:617-27.
22. Guffon N. Clinical presentation in female patients with Fabry disease. J Med Genet 2003;40:e38.
23. Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M, Feriozzi S, Gabrielli O, Barone R, Pistone G, Spisni C, Ricci R, Zammarchi E. Fabry disease: molecular studies in Italian patients, and X inactivation analysis in manifesting carriers. J Med Genet 2003;40:e103.
24. Rodriguez-Mari A, Coll MJ, Chabas A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations, and identification of a homozygous female. Hum Mutat 2003;22:258.
25. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 360 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42.
26. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Naturwissenschaften 1961;190:372-3.
27. Lyon MF. X-chromosome inactivation, and human genetic disease. Acta Paediatr Suppl 2002;91:107-12.
28. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
29. Bergner M. Quality of life, health status, and clinical research. Med Care 1989;27:S148-56.
30. Santanello NC, Baker D, Cappelleri JC, Copley-Merriman K, DeMarinis R, Gagnon JP, Hsuan A, Jackson J, Mahmoud R, Miller D, Morgan M, Osterhaus J, Tilson H, Willke R. Regulatory issues for health-related quality of life - PhRMA Health Outcomes Committee worbhop, 1999. Value Health 2002;5:14-25.
31. Hennessy CH, Moriarty DG, Zack MM, Scherr PA, Brackbill R. Measuring health-related quality of life for public health surveillance. Public Health Rep 1994;109:665-72.
32. Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL. Quality of life of patients with Fabry disease. Qual Life Res 2002;11:317-27.
33. Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with, anderson Fabry disease before therapeutic intervention. Qual Life Res 2002;11:127-33.
34. World Health Organization. World Health Organization Quality of Life assessment (WHOQOL). Position paper from the World Health Organization. Soc Sci Med 1995;41:1403-9.
35. World Health Organization. World Health Organization constitution. Basic documents, Geneva, Switzerland, 1948.
36. van Agt HM, Essink-Bot ML, Krabbe PF, Bonsel GJ. Test-retest reliability of health state valuations collected with the EuroQol questionnaire. Soc Sci Med 1994;39:1537-44.
37. Brooks R. Quality of life measures. Crit Care Med 1996;24:1769.
38. Kind P, Hardman G, Macran S. UK population norms for EQ-5D, Discussion paper. York: Centre for Health Economics, 1999:172.
39. Macran S, Kind P. "Death", and the valuation of health-related quality of life. Med Care 2001;39:217-27.
40. Cleeland CS. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 2002;91:43-7.
41. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
42. Breitbart W, Rosenfeld B, Passik S, Kaim M, Funesti-Esch J, Stein K. A comparison of pain report, and adequacy of analgesic therapy in ambulatory AIDS patients with, and without a history of substance abuse. Pain 1997;72:235-43.
43. Sculco AD, Paup DC, Fernhall B, Sculco MJ. Effects of aerobic exercise on low back pain patients in treatment. Spine. J 2001;1:95-101.
44. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis 2003;42:1239-47.
45. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 2004;5:133-7.
46. Bryan S, Ratcliffe J, Neuberger JM, Burroughs AK, Gunson BK, Buxton MJ. Health-related quality of life following liver transplantation. Qual Life Res 1998;7:115-20.
47. Conner-Spady B, Cumming C, Nabholtz JM, Jacobs P, Stewart D. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual Life Res 2001;10:479-86.
48. Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life, and utility in patients with non-small cell lung cancer. Quality-or-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001;19:855-63.
49. Cleemput I, Kesteloot K, De Geest S, Dobbels F, Vanrenterghem Y. Health professionals' perceptions of health status after renal transplantation: a comparison with transplantation candidates' expectations. Transplantation 2003;76:176-82.